Clinical Trials
25 trialsNCT02961101 2026-01-22
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06090864 2025-10-20
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT03383094 2025-10-07
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
University of California, San Diego
Phase 2 Active not recruiting
NCT03581786 2025-09-02
The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Completed
NCT07022002 2025-08-03
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2 Recruiting
NCT07098949 2025-08-01
Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
Guangzhou University of Traditional Chinese Medicine
Phase NA Not yet recruiting
NCT03257267 2025-04-08
Study of Cemiplimab in Adults With Cervical Cancer
Regeneron Pharmaceuticals
Phase 3 Completed
NCT06670911 2025-02-24
ACCESS-I
Instituto Nacional de Cancer, Brazil
Phase 2 Recruiting
NCT06750952 2024-12-27
iTHYM
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05364905 2023-09-06
ENDOVIE
ARCAGY/ GINECO GROUP
Completed
NCT05718466 2023-07-17
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Henry Ford Health System
Phase 3 Completed
NCT05512182 2023-06-15
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
Yonsei University
Phase 2 Withdrawn
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT03236857 2023-05-22
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
AbbVie
Phase 1 Completed
NCT01809379 2022-07-08
Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
Ruhr University of Bochum
Phase 2 Completed
NCT02298166 2021-10-06
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm
Phase 3 Terminated
NCT05059782 2021-09-28
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
Xi'an Jiaotong University
Phase NA Unknown
NCT03297528 2020-03-10
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Peking University People's Hospital
Phase 2 Unknown
NCT02350712 2018-09-11
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
Daiichi Sankyo
Phase 1 Completed
NCT00993694 2017-04-17
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
Vanderbilt University Medical Center
Completed
NCT01841021 2017-01-19
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT02997241 2016-12-20
CCTDRP
MyGenostics Inc., Beijing
Phase NA Unknown
NCT02410187 2016-03-03
SBRT for Extra-cranial Oligorecurrent Tumor
Korea Cancer Center Hospital
Phase 2 Unknown
NCT00458744 2014-08-08
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
Children's Oncology Group
Phase 1 Withdrawn
NCT00005969 2012-02-20
Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease
M.D. Anderson Cancer Center
Phase 2 Withdrawn